Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist
Marc A. Pfeffer,Eugene Braunwald +1 more
Reads0
Chats0
TLDR
Patients with diastolic dysfunction and preserved ejection fraction exhibit a statistically significant correlation between the level of circulating aldosterone and left ventricular mass, and the central role of interstitial fibrosis in the heart (and perhaps the kidney as well) in HF makes these observations particularly important.About:
This article is published in JAMA Cardiology.The article was published on 2016-04-01 and is currently open access. It has received 33 citations till now. The article focuses on the topics: Heart failure with preserved ejection fraction & Eplerenone.read more
Citations
More filters
Journal ArticleDOI
Machine learning can predict survival of patients with heart failure from serum creatinine and ejection fraction alone
Davide Chicco,Giuseppe Jurman +1 more
TL;DR: Analysis of a dataset of 299 patients with heart failure collected in 2015 shows that serum creatinine and ejection fraction are sufficient to predict survival of heart failure patients from medical records, and that using these two features alone can lead to more accurate predictions than using the original dataset features in its entirety.
Journal ArticleDOI
Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
TL;DR: The evidence suggested that ACEI treatment likely has little or no effect on cardiovascular mortality, all-cause mortality, heart failure hospitalisation, or quality of life, and the quality of evidence assessed as moderate was low.
Journal ArticleDOI
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives
TL;DR: The clinical studies and mechanisms thought responsible for their benefits are reviewed in an attempt to increase their use in guideline eligible patients with HF as well as to provide the basis for understanding potential new opportunities for their use.
Journal ArticleDOI
Gliflozins in the Management of Cardiovascular Disease
TL;DR: Gliflozins as mentioned in this paper lower blood glucose and glycated hemoglobin in patients with type 2 diabetes without causing hypoglycemia, and improve cardiac function in patients who have heart failure with or without Type 2 diabetes.
Journal ArticleDOI
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
Subha V. Raman,Kan N Hor,Wojciech Mazur,Xin He,John T. Kissel,Suzanne Smart,Beth McCarthy,Sharon L. Roble,Sharon L. Roble,Linda H. Cripe +9 more
TL;DR: Eplerenone offers effective and safe cardioprotection for boys with DMD, particularly when started at a younger age, and is a useful clinical therapeutic option, particularly if treatment is initiated earlier in life when cardiac damage is minimal.
References
More filters
Journal ArticleDOI
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Faiez Zannad,John J.V. McMurray,Henry Krum,Dirk J. van Veldhuisen,Karl Swedberg,Harry Shi,John Vincent,Stuart J. Pocock,Bertram Pitt +8 more
TL;DR: Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Journal ArticleDOI
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt,Marc A. Pfeffer,Susan F. Assmann,Robin Boineau,Inder S. Anand,Brian Claggett,Nadine Oliveira Clausell,Akshay S. Desai,Rafael Diaz,Jerome L. Fleg,Ivan Gordeev,Brian Harty,John F. Heitner,Christopher T. Kenwood,Eldrin F. Lewis,Eileen O'Meara,Jeffrey L. Probstfield,Tamaz Shaburishvili,Sanjiv J. Shah,Scott D. Solomon,Nancy K. Sweitzer,Song Yang,Sonja M. McKinlay +22 more
TL;DR: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.
Related Papers (5)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt,Marc A. Pfeffer,Susan F. Assmann,Robin Boineau,Inder S. Anand,Brian Claggett,Nadine Oliveira Clausell,Akshay S. Desai,Rafael Diaz,Jerome L. Fleg,Ivan Gordeev,Brian Harty,John F. Heitner,Christopher T. Kenwood,Eldrin F. Lewis,Eileen O'Meara,Jeffrey L. Probstfield,Tamaz Shaburishvili,Sanjiv J. Shah,Scott D. Solomon,Nancy K. Sweitzer,Song Yang,Sonja M. McKinlay +22 more
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
Marc A. Pfeffer,Brian Claggett,Susan F. Assmann,Robin Boineau,Inder S. Anand,Nadine Oliveira Clausell,Akshay S. Desai,Rafael Diaz,Jerome L. Fleg,Ivan Gordeev,John F. Heitner,Eldrin F. Lewis,Eileen O'Meara,Jean L. Rouleau,Jeffrey L. Probstfield,Tamaz Shaburishvili,Sanjiv J. Shah,Scott D. Solomon,Nancy K. Sweitzer,Sonja M. McKinlay,Bertram Pitt +20 more
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more